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Abstract
Background: Rapid reperfusion following ischemia is the most effective therapy in stroke therapy. However, the
success may be compromised by ischemia & reperfusion (I/R) injury and at the human blood–brain barrier (BBB),
therefore the effects on transendothelial transport are of special interest. Current studies suggest the ATP-binding
cassette (ABC) transporters to be regulated upon ischemic stroke in a way that impedes the effects of drug therapy.
The immortalised human brain microvascular endothelial cell line hCMEC/D3 provides most of the unique
properties of the BBB with respect to transport and might be a reliable in vitro model to study transendothelial
transport after I/R.
Methods: We exposed hCMEC/D3 cells to 24 hours of hypoxia alone and to hypoxia followed by 60 min of
reoxygenisation as an in vitro model for I/R. Western blot showed mild upregulation of hypoxia inducible factor
(HIF-1α) after hypoxia alone and RNA lysates were analysed with a well-established real-time RT-PCR-based TaqMan
low-density array detecting 47 of 48 known human ABC transporters.
Results: No significant increases of ABC mRNA expression levels were detected neither in hypoxic nor in I/R
samples. However, slight decrease of ABCC1 in hypoxic and I/R samples and of ABCA10 and ABCD3 in I/R samples
was observed.
Conclusion: Our data suggests that hCMEC/D3 cell line and – at the moment – in vitro models in general are a
poor basis for stroke research but may be enhanced by co-culturing more cells of the neurovascular unit inducing
an overall ischemic response at the BBB.
Keywords: Blood–brain barrier, Ischemia/reperfusion injury, Hypoxia-inducible factor, Multidrug resistance, ABC
transporters, Stroke
Background
The successful rescue of penumbral brain tissue by rapid
reperfusion may be compromised by ischemia/reperfusion
injury (I/R) and other secondary events, amongst them
post-ischemic inflammatory response, excitotoxicity, excess
of reactive oxygen species (ROS), and induction of apop-
totic neuronal cell death [1-3]. The cerebral endothelium,
which forms the blood–brain barrier (BBB) in-vivo, may
play a crucial role in post-ischemic reperfusion for several
reasons: 1.) it is the primary site where reperfusion occurs,
2.) it allows interaction between the brain’s and body’s im-
mune system and, 3.) it strongly interacts with other cell
types of the neurovascular unit via cell-cell, cell-matrix and
neuro-endocrine cross talk, amongst others, determining
the overall cerebral response to ischemia [4-6]. Several
studies with I/R stroke models demonstrated a dynamic,
even biphasic BBB permeability increase, whereas in clin-
ical stroke neurology only early post-ischemic BBB disrup-
tion has been associated with life threatening oedema
formation and increased risk of symptomatic intracerebral
hemorrhage [7-10]. However, other than BBB tight junction
integrity several other BBB functions may be compromised
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and contribute to I/R injury. Especially transendothelial
transport is of special interest for I/R injury and may influ-
ence brain nutrition, systemic response to brain ischemia,
and even drug therapy of the brain [11,12].
Drug therapy is compromised by endothelial efflux trans-
porters normally responsible for brain detoxification, and
the best-characterised efflux transporters of the brain’s
endothelium are p-glycoprotein (P-gp, MDR1, ABCB1) and
breast cancer resistance protein (BCRP, ABCG2) [11,13,14].
Both belong to the ATP-binding cassette (ABC) transporter
family, which comprises 48 multispan membrane proteins
and is further divided into seven subfamilies (from ABCA
to ABCG) according to sequence homology [15]. ABC
transporters either promote or regulate the transport of
specific substrates across various biological membranes, in-
cluding sugars, amino acids, metal ions, peptides, and pro-
teins as well as a large number of hydrophobic compounds
and metabolites, and are abundantly expressed at the BBB
[16-19]. Moreover, several ABC-transporters at the BBB
play an important role in multi-drug resistance thereby
offering brain protection from toxic compounds by acting
as efflux transporters, and unfortunately for several drugs
causing multidrug resistance [11,19,20].
Only few studies investigate the regulation of ABC-
transporters upon ischemia, I/R and regeneration. In vivo
studies suggest that the expression of ABC transporters is
upregulated upon ischemia, impeding the delivery of drugs
into the brain [21,22]. A recent study by Patak et al. inves-
tigated the regulation of ABCB1 and ABCC1 by hypoxia in
immortalised human brain microvascular endothelial cells
(hCMEC/D3), a very common and well characterised cell
line for transport studies as unique properties of the BBB
persist [23-26]. Surprisingly, Patak et al. found no changes
of ABCB1 and ABCC1 expressions neither on the mRNA
nor protein level immediately after hypoxia. The authors
speculated that regulation of ABCB1 and ABCC1 as seen
in cerebral ischemia could depend on other factors than
hypoxia, such as glucose deprivation or reoxygenation.
In this study we characterise the immortalised human
cerebral endothelial cell line hCMEC/D3 performing profil-
ing of mRNA expression of 47 human ABC transporters
and compared mRNA expression during normoxia, after 24
hours of hypoxia and after 24 hours of hypoxia followed by
60 min of reoxygenation resembling I/R with a reference
panel from a large variety of other human tissues (Human
universal reference total RNA). For the analysis, we used a
well-established real-time RT-PCR-based TaqMan low-
density array (TLDA) [27,28] and compared transcript
levels of hypoxic and I/R samples to normoxic samples.
Methods
The hCMEC/D3 cell line
The hCMEC/D3 cell line was developed by Weksler
et al. by coexpressing hTERT and the SV40 large T
antigen via a highly efficient lentiviral vector system in a
primary cell culture from an epileptic region from the
temporal lobe [23,29]. In brief, the goal was to establish
a stable, fully characterised and well-differentiated
human brain endothelial cell line which retains most of
the unique properties of the BBB superior to other com-
plex co-culture BBB models [30,31]. After several
attemps [23,32-35] the hCMEC/D3 cell line was the first
human brain endothelial cell line to retain most of the
unique properties of the BBB without undergoing the
rapid dedifferentiation and senescence characteristical
for primary cultures of human brain endothelial cells.
Cell culture
hCMEC/D3 cells (passages 35–38) were grown in EBM-
2 medium (Lonza, Verviers, Belgium) supplemented with
hydrocortisone, ascorbate, gentamycin, VEGF, IGF-1,
EGF, basic FGF and 2,5 % fetal calf serum as previously
described [23] and called microvascular endothelial cell
medium-2 (EGM-2MV). The cells were plated out in
T75 flasks coated with type I collagen (PAN-Biotech,
Aidenbach, Germany) and grown at 37°C in a humidified
atmosphere of 5 % CO2. Cell flasks for ischemia and I/R
used a vent/close closure and were placed in a hypoxia
chamber with their closure slightly unclosed for 1 hour
for equilibration at reduced oxygen level (oxygen con-
centration 3 %), then were completely closed and incu-
bated for 23 hours. I/R samples were afterwards put back
in a chamber at 37°C and humidified atmosphere of 5 %
CO2 with their closure slightly unclosed to enable equili-
bration to normoxia for 60 min.
RNA isolation, reverse transcription, Quantitative real-
time PCR and Data analysis were performed as previ-
ously published [27] with the following differences:
RNA isolation
For cell RNA isolation from cultured cells we used the
RNeasy Mini Kit (Qiagen, Hilden, Germany) according
to the manufacturer’s instructions.
Data analysis
Micro Fluidic Cards were analyzed with relative quantity
(RQ) documents and the RQ Manager Software for auto-
mated data analysis. We performed 3 experiments for nor-
moxic and hypoxic samples and two for I/R samples.
Expression values for target genes were normalised to the
concentration of 18 S rRNA. For each experiment, gene
expression values were calculated on the basis of the com-
parative threshold cycle (Ct) method, in which normoxic
samples were designated as the calibrator to which the
other samples were compared. In short, the Ct data for all
human ABC transporters and 18 S rRNA in each sample
were used to create ∆Ct values (CtABC transporter –Ct18S rRNA).
For this calculation, the mean Ct over all experiments
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was used. Thereafter, ∆∆Ct values were calculated by
subtracting the ∆Ct of the calibrator from the ∆Ct
value of each target. The RQs were calculated using
the equation: RQ = 2-∆∆Ct. Genes that were regulated
more than 2-fold (≥2.0 or ≤0.5) were considered as sig-
nificantly regulated. The standard deviations (SD) for
∆Ct and ∆∆Ct values were calculated from the single Ct
values with the equation: SD∆Ct = √(SDtABC transporter
2 +
SDt18S rRNA
2 ). The ranges of the RQ values were calcu-
lated by use of the equations: RQmin = 2
-∆∆Ct-SD and
RQmax = 2
-∆∆Ct+SD.
Antibodies
The polyclonal goat antibody against human HIF-1α was
purchased from Santa Cruz (sc-8711, Heidelberg,
Germany). Molecular Weight of HIF-1α is 132 kDa. The
donkey polyclonal, horse radish peroxidase (HRP)-
conjugated antibody raised against goat IgG was purchased
from Dianova (Hamburg, Germany).
Western Blot
Briefly, cell lysates were prepared using RIPA lysis buffer
(50 mM Tris pH 7.4, 0.1 % SDS, 1 % Nonidet P40, 0.5 % so-
dium deoxycholate, 150 mM NaCl) containing protease in-
hibitor cocktail (Roche, Mannheim, Germany). Protein
concentrations were quantified using a Bicinchoninic Acid-
Assay. Protein samples were separated on 10 % NuPAGE
Novex Bis-Tris gels (Invitrogen, Karlsruhe, Germany) and
blotted onto PVDF membranes according to manufacturer’s
instruction. After the transfer of 100 μg of each control and
24 hours hypoxia blocking of unspecific binding sites was
achieved by incubation in TPBS (50 mM Tris/HCl,
150 mM NaCl) containing 0.1 % Tween 20 and 3 %
skimmed milk. Washed membranes were incubated over-
night at 4°C with antibody against HIF-1α (1:500 in 3 %
skimmed milk). Following 1 hour incubation with the HRP-
conjugated secondary anti-goat antibody (1:5000 in 3 %
skimmed milk), the target protein was detected with the
chemiluminescence HRP Substrate (Millipore, Schwalbach,
Germany) using an X-Omat M35 Film Processor (Kodak,
Stuttgart, Germany).
Results
Induction of HIF-1α under hypoxia
After ischemia cell culture media showed a reddish
colour indicating low pH as observed in hypoxia. To
confirm hypoxia, cell lysates were analysed by Western
blot to detect the protein expression of HIF-1α. HIF-1α
was increased in a sample that underwent 24 hours of
hypoxia as compared to the normoxic control (Figure 1).
We conclude that our in vitro model of ischemia did in-
deed induce hypoxia in hCMEC/D3 samples.
Expression analysis of ABC-transporters in hCMEC/D3 cell
line during normoxia
To provide a profile of mRNA expression of human
ABC transporters in the hCMEC/D3 cell line, expression
levels were determined with TLDA technique. Ct values
were compared to human universal reference calibrator
RNA (huRNA) and ∆Ct values were calculated (means ±
SD). Results are displayed as a dot code for high (●●●),
medium (●●) and low (●) expressions, which are based
on ∆Ct values (Table 1). For this analysis, the range be-
tween the lowest ∆Ct value and the highest ∆Ct value of
genes expressed was divided linearly into three groups
for high, medium and low expressions. Genes with not at
least half of their Ct values below 35 cycles were defined
as absent.
In cells of the hCMEC/D3 cell line we found no expres-
sion for ABCA12, ABCA13, ABCB4, ABCB5, ABCB11,
ABCC6, ABCC7, ABCC8, ABCC9, ABCC11, ABCD2,
ABCG4, ABCG5 and ABCG8. At least low levels of ex-
pression were found for ABCA1, ABCA4, ABCA8,
ABCA9, ABCA10, ABCC2, ABCC5 and ABCD1, whereas
medium levels were found for ABCA2, ABCA3, ABCA7,
ABCB6, ABCB8, ABCB9, ABCB10, ABCC3, ABCC10,
ABCD4, ABCF1, ABCG1 and ABCG2. High expression
levels were found for ABCA5, ABCA6, ABCB1, ABCB2,
ABCB3, ABCB7, ABCC1, ABCC4, ABCD3, ABCE1,
ABCF2 and ABCF3.
Also displayed in Table 1 are RQ values of hCMEC/D3
gene expression compared to the human universal refer-
ence total RNA. Values are the mean (range). A high basal
expression level, which was defined as a two-fold higher
expression than in the pooled tissue RNA, is depicted in
red. Low basal expression level, defined as two-fold lower
expression than in the pooled tissue RNA, is depicted in
blue. Most genes had high basal expression levels – some
as high as up to almost 30-fold in the case of ABCB1 –
and ABCA2, ABCA8 and ABCC2 revealed decreased basal
expression levels. The expression levels of ABCA1,
ABCA9, ABCA10, ABCB9, ABCG1, and ABCG2 were
not changed. We could not determine a fold change value
for ABCA7, because it could not be detected in the pooled
tissue RNA. For an overview of RQ values, see also
Figure 2.
Expression analysis of ABC-transporters in hCMEC/D3 cell
line during hypoxia and hypoxia plus reoxygenation
To compare the effects of ischemia or I/R on mRNA ex-
pression of human ABC transporters in the hCMEC/D3
cell line, we determined expression levels for samples which
had undergone 24 hours of hypoxia and those who had
undergone 24 hours of hypoxia and then 60 minutes of
reoxygenation (I/R) to normoxic samples. For this analysis,
we compared the fold change (RQ) in ABC transporter ex-
pression of hypoxic and I/R samples to normoxic samples
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(Table 2). Values are the mean (range). Genes that are regu-
lated more than 2-fold (≥2.0 or ≤0.5) are considered as sig-
nificantly regulated. Induced genes are depicted in red,
down-regulated genes are depicted in blue.
No genes were induced under hypoxia or I/R. We
observed a significant down-regulation for ABCA10 in I/R
samples, but no further changes for mRNA in the ABCA
family. The ABCA family is mainly involved in lipid trans-
ports. We did not discover any significant changes in the
ABCB family, whose transporters functions in multi-drug
resistance (ABCB1), mitochondrial activity (ABCB6,
ABCB7, ABCB8, ABCB10) or lysosomal activity (ABCB9).
Of the ABCC family, only mRNA levels of ABCC1, a
multi-drug resistance protein, were decreased both in hyp-
oxic and I/R samples. No significant changes were found
for the other members of the family, which is predomin-
antly involved in multi-drug resistance. We noted a down-
regulation of ABCD3 in I/R samples, but no other expres-
sion alterations were significant in the ABCD, ABCE,
ABCF and ABCG family. Members of the ABCD family
are only found in peroxysomes and are involved in very
long chain fatty acid oxidation. ABCE1, the only member
of the ABCE family, inhibits the RNAseL protein and is es-
sential for the assembly of immature human immunodefi-
ciency virus capsids. ABCF transporters, like ABCF1, have
no transmembrane domains and may play a role in en-
hancement of protein synthesis and the inflammation
process. ABCG1 is involved in cholesterol efflux, ABCG2
is a drug-resistance gene. The other members of the
ABCG family are mainly involved in cholesterol and sterol
transport in various organs, but were not detected in
hCMEC/D3 cell line. Overall, we noticed a general ten-
dency towards down-regulation for all genes in hypoxic
and I/R samples except for ABCA6 and ABCC2 of I/R
samples (Table 2).
Discussion
In this study, we have employed a TaqMan-based low-
density array for mapping mRNA expression profiles in
hCMEC/D3 cell line for 47 of the known 48 ABC trans-
porters. We compared expression levels of normoxic
hCMEC/D3 cells to hCMEC/D3 samples which had
undergone 24 hours of hypoxia and to hCMEC/D3 sam-
ples which were reoxygenated for 60 minutes after 24
hours of sustained hypoxia (a model for I/R). Our main
aim was to investigate, whether the developed hCMEC/D3
cell line [23] might be a reliable and accessible in vitro
model to study the effects of ischemia upon ABC
transporters. Surprisingly, we did not detect a significant
up-regulation of any ABC transporter mRNA neither in
hypoxic hCMEC/D3 nor in cells subjected to I/R.
Most of our results regarding overall expression of
ABC transporter mRNA in normoxic samples are in
concordance with previously published data for hCMEC/
D3 cell line [25,36], for example the rather high expres-
sion of ABCB1, ABCB3 and ABCC1. Comparison is diffi-
cult though due to different parameters, housekeeping
genes or calibrators [25,36]. Notable are the differences
of expression in hCMEC/D3 cell line compared to ex-
pression levels in the adult human BBB: Dauchy et al.
[37] showed no detection for ABCC2 and ABCC3
mRNA neither in cortex samples nor in the correspond-
ing isolated microvessel fraction, both of which could be
detected in our study in hCMEC/D3 cell line (Table 1).
However, for ABCC2 the discrepancy may be attributed
to the fact, that the hCMEC/D3 cell line is based on
samples taken from epileptic regions [23] and ABCC2
expression is known to be found in brain samples from
epileptic regions [38]. The known upregulation of several
ABC transporters in samples of epileptic regions [39]
might also be the cause for further controversies such as
the rather high ABCC1 mRNA levels or the absence of
genes in our study, for example ABCC6 and ABCC11
Figure 1 Upregulation of HIF-1 α Western blot after 24 hrs
hypoxia compared to control at 130 kDa (right arrow).
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Table 1 Expression of ABC transporters in the immortalised human brain microvascular endothelial cell line hCMEC/D3
Gene Assay ID Expression Normoxic ∆Ct (SD) RQ (RQ Range)
ABCA1 Hs00194045_m1 ● 16.31 (0.58) 0.65 (0.44-0.97)
ABCA2 Hs00242232_m1 ●● 15.38 (0.54) 0.42 (0.29-0.62)
ABCA3 Hs00184543_m1 ●● 14.83 (0.61) 7.85 (5.15-11.97)
ABCA4 Hs00184367_m1 ● 17.21 (0.62) 2.20 (1.43-3.38)
ABCA5 Hs00363322_m1 ●●● 12.27 (0.46) 6.54 (4.75-9.01)
ABCA6 Hs00365329_m1 ●●● 12.82 (0.49) 22.92 (16.37-32.09)
ABCA7 Hs00185303_m1 ●● 15.77 (0.47) n.a.a
ABCA8 Hs00200350_m1 ● 17.90 (0.93) 0.31 (0.16-0.60)
ABCA9 Hs00329320_m1 ● 17.94 (0.58) 0.66 (0.44-0.98)
ABCA10 Hs00365268_m1 ● 17.04 (0.61) 1.30 (0.85-1.98)
ABCA12 Hs00292421_m1 n.e.b
ABCA13 Hs00541549_m1 n.e.
ABCB1 Hs00184491_m1 ●●● 11.91 (0.40) 29.84 (22.55-39.48)
ABCB2 Hs00184465_m1 ●●● 12.44 (0.40) 9.68 (7.31-12.81)
ABCB3 Hs00241060_m1 ●●● 13.16 (0.43) 20.05 (14.90-26.98)
ABCB4 Hs00240956_m1 n.e.
ABCB5 Hs00698751_m1 n.e.
ABCB6 Hs00180568_m1 ●● 14.08 (0.43) 2.62 (1.95-3.51)
ABCB7 Hs00188776_m1 ●●● 13.47 (0.36) 6.02 (4.70-7.72)
ABCB8 Hs00185159_m1 ●● 15.29 (0.46) 4.45 (3.23-6.13)
ABCB9 Hs00608640_m1 ●● 15.71 (0.71) 0.92 (0.56-1.50)
ABCB10 Hs00429240_m1 ●● 14.18 (0.37) 3.00 (2.33-3.87)
ABCB11 Hs00184824_m1 n.e.
ABCC1 Hs00219905_m1 ●●● 12.76 (0.47) 20.95 (15.10-29.07)
ABCC2 Hs00166123_m1 ● 18.41 (0.43) 0.44 (0.33-0.59)
ABCC3 Hs00358656_m1 ●● 14.44 (0.42) 8.23 (6.17-10.98)
ABCC4 Hs00195260_m1 ●●● 12.49 (0.38) 8.64 (6.64-11.24)
ABCC5 Hs00194701_m1 ● 17.44 (0.51) 3.06 (2.15-4.37)
ABCC6 Hs00184566_m1 n.e.
ABCC7 Hs00357011_m1 n.e.
ABCC8 Hs00165861_m1 n.e.
ABCC9 Hs00245832_m1 n.e.
ABCC10 Hs00375716_m1 ●● 15.14 (0.45) 3.72 (2.72-5.10)
ABCC11 Hs00261567_m1 n.e.
ABCD1 Hs00163610_m1 ● 17.80 (0.77) 11.53 (6.77-19.64)
ABCD2 Hs00193054_m1 n.e.
ABCD3 Hs00161065_m1 ●●● 13.41 (0.36) 10.20 (7.94-13.11)
ABCD4 Hs00245340_m1 ●● 14.87 (0.45) 4.59 (3.37-6.25)
ABCE1 Hs00759267_s1 ●●● 11.80 (0.34) 10.10 (7.97-12.79)
ABCF1 Hs00153703_m1 ●● 15.21 (0.44) 2.44 (1.80-3.31)
ABCF2 Hs00606493_m1 ●●● 11.97 (0.47) 3.22 (2.33-4.46)
ABCF3 Hs00217977_m1 ●●● 13.58 (0.32) 4.21 (3.36-5.27)
ABCG1 Hs00245154_m1 ●● 15.48 (0.36) 1.05 (0.82-1.35)
ABCG2 Hs00184979_m1 ●● 14.84 (0.50) 1.21 (0.85-1.72)
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(Table 1), which were both detected in other studies
[37,40]. Expression levels differed all the same: Dauchy
et al. [37] found ABCG2 mRNA levels to be approxi-
mately sevenfold higher than ABCB1 levels, whereas in
our study and in another study from Dauchy et al. [25]
ABCG2 mRNA levels were approximately sevenfold
lower than ABCB1 mRNA levels. These findings strongly
suggest a significant contrast in expression patterns of
ABC genes in hCMEC/D3 cell line to human BBB sam-
ples and underline findings of other studies, in which
Table 1 Expression of ABC transporters in the immortalised human brain microvascular endothelial cell line hCMEC/D3
(Continued)
ABCG4 Hs00223446_m1 n.e.
ABCG5 Hs00223686_m1 n.e.
ABCG8 Hs00223690_m1 n.e.
a) ABCA7 mRNA could not be detected in human reference RNA calibrator.
b) n.e., not expressed.
a
b
0
0.2
0.4
0.6
0.8
1
1.2
RQ
ABCA family
Hypoxia
I/R
0
0.2
0.4
0.6
0.8
1
RQ
ABCB family
Hypoxia
I/R
d
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1
1.2
ABCC1 ABCC2 ABCC3 ABCC4 ABCC5ABCC10
ABCC family
Hypoxia
I/R
0
0.2
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0.6
0.8
1
1.2
ABCD1 ABCD3 ABCD4 ABCE1
RQ
ABCD and ABCE family
Hypoxia
I/R
c
RQ
e
0
0.2
0.4
0.6
0.8
1
1.2
ABCF1 ABCF2 ABCF3 ABCG1 ABCG2
RQ
ABCF and ABCG family
Hypoxia
I/R
Figure 2 (a-e) Expression and regulation of ABC transporters in the immortalised human brain microvascular endothelial cell line
hCMEC/D3 after hypoxia and after ischemia/reperfusion compared to normoxic samples.
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ABCB1, ABCC1 and ABCG2 mRNA expression differed
greatly from expression levels in human brain microves-
sels [25].
Regarding the effects of hypoxia on the expression of
ABC transporters, our findings indicate a tendency to-
wards down-regulation for most ABC transporter genes
in hypoxia, especially taking into consideration the RQ
ranges (Table 2), but only ABCC1 was significantly
down-regulated after 24 hours of hypoxia. There is very
few data on the effects of hypoxia on ABC gene expres-
sion in brain endothelial cells in vitro: Only one recently
published study from Patak et al. [24] investigated the
effects of hypoxia on ABCC1 and ABCB1 gene expres-
sion, but found no change in hCMEC/D3 cell line after 4
hours of hypoxia (nor in protein levels after 4 to 48
hours of hypoxia for that matter). The difference in
ABCC1 expression as well as the lower RQ of ABCB1 in
our study (0.57 versus almost 1 in the study from Patak
et al.) may be mainly attributed to the increased duration
of hypoxia in our study and not to variance, since even
RQmax of ABCB1 did not reach 1 in our study. Three
more studies focused on ABCB1 mRNA expression in
rat brain endothelial cells: Xiao-Dong et al. [41] showed
that repetitive/temporal hypoxia of 15 minutes once a
day (by covering the cells in paraffin oil) over a span of
8 days induced increase of ABCB1 levels, Felix and Barrand
[42] found increased levels of ABCB1 following 6 hours
of hypoxia, Robertson et al. [43] found no changes after
6 hours of hypoxia alone. These results in rat brain
endothelial cells are largely in contrast to our findings,
where no change of ABCB1 levels could be detected.
This may be due to the longer hypoxic duration in our
study, leading to more cell death and general down-
regulation of genes, but in synopsis with the aforemen-
tioned results from Patak et al. the different results are
probably related to interspecies differences. Thus, compari-
son between results in rat brain endothelial cell lines and
hCEMC/D3 cell line should be viewed critically.
In our samples that were reoxygenated for 60 minutes
after 24 hours of hypoxia, we found significantly
decreased expression levels for ABCA10, ABCC1 and
ABCD3, but no significant changes for other genes. The
mRNA levels of hypoxic cells after reoxygenation tended
to decrease slightly more as compared to hypoxic cells
without reoxygenation. These findings suggest that reox-
ygenation results in additional cell stress.
Compared to the results of in vivo studies, which
investigated the expression of ABC transporters after is-
chemia, our results were controversial: We did not find
any elevated expression of mRNA levels neither after 24
hours of hypoxia nor after 24 hours of hypoxia followed
by 60 minutes of reoxygenation. However, ABCB1
proved to be upregulated on focal cerebral ischemia in
mice [39], but not in rats [44], whereas ABCC8 showed
de novo expression on ischemia in rats [39]. ABCC5 and
ABCG2 showed elevated expression after ischemia in a
rat model for stroke [44].
Differences in cerebral endothelial cell gene expression
from in vivo models and non-immortalised rat and
mouse brain endothelial cell cultures to our results can
be seen as an interspecies difference, but may also be
discussed from the perspective of immortalisation:
Table 2 Expression and regulation of ABC transporters in
the immortalised human brain microvascular endothelial
cell line hCMEC/D3 after hypoxia and after ischemia/
reperfusion
Gene RQ of hypoxic
compared to normoxic
samples (Range)
RQ of I/R
compared to normoxic
samples (Range)
ABCA1 0.79 (0.45-1.38) 0.83 (0.54-1.28)
ABCA2 0.70 (0.42-1.16) 0.70 (0.54-0.91)
ABCA3 0.85 (0.57-1.25) 0.76 (0.59-0.98)
ABCA4 0.55 (0.32-0.94) 0.69 (0.36-1.34)
ABCA5 0.70 (0.47-1.05) 0.63 (0.51-0.78)
ABCA6 0.89 (0.62-1.29) 1.01 (0.63-1.63)
ABCA7 0.90 (0.56-1.45) 0.76 (0.60-0.96)
ABCA8 0.69 (0.42-1.13) 0.62 (0.42-0.92)
ABCA9 0.97 (0.43-2.23) 0.86 (0.52-1.41)
ABCA10 0.69 (0.43-1.11) 0.48 (0.33-0.69)
ABCB1 0.57 (0.39-0.85) 0.60 (0.47-0.75)
ABCB2 0.81 (0.55-1.20) 0.89 (0.70-1.15)
ABCB3 0.54 (0.35-0.85) 0.67 (0.47-0.95)
ABCB6 0.80 (0.50-1.28) 0.58 (0.47-0.71)
ABCB7 0.75 (0.51-1.11) 0.64 (0.51-0.81)
ABCB8 0.76 (0.47-1.22) 0.71 (0.50-1.02)
ABCB9 0.74 (0.48-1.13) 0.51 (0.35-0.75)
ABCB10 0.92 (0.60-1.42) 0.60 (0.46-0.77)
ABCC1 0.48 (0.33-0.71) 0.49 (0.39-0.61)
ABCC2 0.82 (0.48-1.39) 1.03 (0.71-1.51)
ABCC3 0.59 (0.40-0.85) 0.57 (0.44-0.74)
ABCC4 0.54 (0.37-0.79) 0.52 (0.40-0.68)
ABCC5 0.72 (0.45-1.15) 0.75 (0.40-1.42)
ABCC10 0.79 (0.48-1.29) 0.63 (0.48-0.82)
ABCD1 0.52 (0.30-0.90) 0.51 (0.25-1.02)
ABCD3 0.52 (0.34-0.79) 0.40 (0.27-0.61)
ABCD4 0.84 (0.55-1.28) 0.98 (0.63-1.51)
ABCE1 0.60 (0.41-0.87) 0.51 (0.38-0.69)
ABCF1 0.80 (0.53-1.18) 0.70 (0.54-0.91)
ABCF2 0.55 (0.34-0.88) 0.53 (0.43-0.64)
ABCF3 0.76 (0.49-1.20) 0.74 (0.46-1.17)
ABCG1 0.99 (0.68-1.44) 0.97 (0.76-1.23)
ABCG2 0.87 (0.59-1.27) 0.53 (0.36-0.78)
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hCMEC/D3 cell line is immortalised by use of hTERT
and SV 40 large T antigen. hTERT adds a functional tel-
omerase to hCMEC/D3 cells, SV 40 large T antigen
deactivates p53 and pRb, thus inhibiting apoptosis and
facilitating cell proliferation. It seems only plausible, that
a cell line altered in such a way is more resilient when it
comes to oxygen deprivation and/or oxidative stress, for-
cing longer durations of hypoxia in order to observe sig-
nificant changes than one would need in primary cells.
Changes of mRNA expression after hypoxia observed
in vivo could also be attributed to other cells than endo-
thelial cells, for example glial cells or neurons, and dis-
cussed in the interaction within the neurovascular unit
[5,45]. Interestingly, Dazert et al. [44] only found signifi-
cant mRNA upregulation from days 3–14, but not earl-
ier, suggesting that upregulation of ABCG2 and ABCC5
is rather linked to behavioural recuperation than an
imminent effect of hypoxia. Further investigation differ-
entiating between short-term and mid-term effects of
hypoxia and the effect of neuro-endocrine crosstalk i.e.
with ischemic astrocytes within the concept of the neu-
rovascular unit upon the mRNA expression levels of
cerebral endothelial ABC transporters may help to better
characterise ischemia and I/R at the BBB [46].
The study described here, however, has some limitations,
and duration of hypoxia in our hypoxia set up in relation to
HIF-1α expression and therefore changes in ABC trans-
porter expression has not been performed to date. Expres-
sion of HIF isoforms may differ, and Patak et al. showed
that in hCMEC/D3 during hypoxia (at 0 and 1 % oxygen)
HIF-1α and HIF-2α abundance increased within 4 h. HIF-
1α levels then decreased to below detection levels within
16 h of hypoxia and HIF-2α remained elevated even after
48 h. The complex relationships of HIF expression and
changes in ABC transporter expression may be investigated
further, but correlation to the situation in ischemic stroke
may remain critical.
Our findings prove significant for clinical aspects of ABC
transporters: Increased mRNA levels of ABCC8 for example
play an important role in genesis of cerebral edema after is-
chemic stroke [47]. Early administration of glibenclamide
appears to be a potent treatment to reduce vasogenic brain
edema [48]. ABCG2 among other ABC transporters proved
to be upregulated after an ischemic insult in order to prevent
the crossing of toxic compounds over the BBB and might
positively affect neurogenesis [44]. ABCB1, which limits the
access of unwanted substrates to the brain, shows increased
expression under oxidative stress, as it occurs during I/R
[42] and nitric oxide might contribute to this up-regulation
[49]. The hCMEC/D3 cell line however did not show ele-
vated expressions for either ABCB1 or ABCG2 and no ex-
pression at all for ABCC8, depriving us of the opportunity to
study the clinical importance of ABC transporters under
hypoxia or after I/R in an easily accessible model.
Conclusion
We report that the regulation of ABC transporters in
case of ischemic stroke could not be reproduced in vitro
using the hCMEC/D3 cell line as a stroke model. Our
findings on ABC-transporter expression at cerebral
endothelial cells using the hCMEC/D3 cell line differ
largely from previously published in-vivo and in-vitro
studies. Although the hCMEC/D3 cell line recapitulates
most of the unique properties of the blood–brain barrier
and is an excellent tool to study transendothelial trans-
port [23] it may not be suitable for studying endothelial
cell response to ischemia. This is in concordance with
the findings of Balser from our group (data unpublished),
who investigated the effects of hypoxia and repetitive ex-
position of isoflurane and sevoflurane on the expression
of eNOS and iNOS and on the output of NO in
hCMEC/D3 cell line and found no significant changes as
opposed to studies on other (cerebral) endothelial cells.
Furthermore, as Patak et al. noted, the regulation of
ABC transporters seen in cerebral ischemia could de-
pend on other factors than hypoxia alone such as glucose
depletion or reactive oxygen species that are generated
by reoxygenation [24]. At the moment, in vitro models
in general form a poor basis for stroke research but may
be enhanced by adding more cells of the neurovascular
unit [46].
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